Skip to main content
. 2019 Dec 12;20(24):6280. doi: 10.3390/ijms20246280

Figure 2.

Figure 2

Farnesiferol B reduces oxidative stress in ischemia/reperfusion (I/R) kidney. (A) Representative images of immunostaining for NGAL on renal sections from (a) sham, (b) I/R, (c) I/R + Farnesiferol B  and (d) sham +  Farnesiferol B groups (scale bar 50 μm). (B) urinary neutrophil gelatinase-associated lipocalin (NGAL), (C) urinary H2O2, and kidney mRNA levels of (D) Nrf2 and (E) HO-1 were analyzed. n = 6 mice/group. Data are means ± SD, one-way ANOVA with Bonferroni’s test. * p < 0.05. (F) Representative images of immunostaining for 4-HNE on renal sections from (a) sham, (b) I/R, (c) I/R + Farnesiferol B  and (d) sham + Farnesiferol B groups (scale bar 50 μm). (G) kidney malondialdehyde (MDA), (H) kidney GSH, and kidney mRNA levels of (I) Gpx4 were analyzed. n = 6 mice/group. Data are means ± SD, one-way ANOVA with Bonferroni’s test. * p < 0.05.